Twice-Daily Deuruxolitinib Significantly Improves Alopecia Areata Over 24 Weeks: Study Dr Riya Dave11 Oct 2024 8:00 PM ISTResearchers found that twice-daily deuruxolitinib (Leqselvi), at an 8 mg dose, significantly improved hair satisfaction of patients with severe...
Active ritlecitinib may improve hair growth in patients with alopecia areata: Study Jacinthlyn Sylvia7 Oct 2024 8:00 PM ISTA new study published in the journal of Dermatology suggests that the Alopecia areata patients who were receiving doses of active ritlecitinib...
Sun Pharma presents new clinical efficacy, safety data in severe dermatological conditions at 2024 EADV Congress Ruchika Sharma27 Sept 2024 3:51 PM ISTMumbai: Sun Pharmaceutical Industries Limited has announced that it will present abstracts across its dermatology portfolio at the 33rd European...
Study Confirms Baricitinib's Effectiveness for Severe Alopecia Areata and Advocates for Early Trichoscopy Medha Baranwal17 Sept 2024 9:45 PM ISTItaly: A recent 24-week study conducted in Italy has yielded promising results regarding the effectiveness and safety of baricitinib for patients with...
Eli Lilly, EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries Ruchika Sharma8 Sept 2024 10:00 AM ISTIndianapolis: Eli Lilly and Company and EVA Pharma have announced that the companies have entered into an agreement to expand access to...
Obese children more likely to develop skin conditions related to the immune system, suggests study Dr. Kamal Kant Kohli23 Aug 2024 9:15 AM ISTChildhood obesity can contribute to the development of common immune-mediated skin diseases (IMSDs), such as alopecia areata, atopic dermatitis, and...
Dupilumab Shows Promising Results for Hair Regrowth in Pediatric Alopecia Areata, with No New Safety Concerns: Study Medha Baranwal17 Aug 2024 9:30 AM ISTUSA: A real-world, single-center observational study revealed that dupilumab significantly enhanced hair regrowth in pediatric patients with alopecia...
FDA approves oral deuruxolitinib for severe alopecia areata Dr. Kamal Kant Kohli29 July 2024 9:45 PM ISTThe US Food and Drug Administration (FDA) has approved oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2 deuruxolitinib (Lesqselvi) 8 mg...
Sun Pharma gets USFDA nod for alopecia areata drug Leqselvi Ruchika Sharma26 July 2024 11:34 AM ISTLEQSELVI is a new, twice daily oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2.
Researchers develop microneedle patch to reverse hair loss caused by autoimmune disease Dr. Kamal Kant Kohli10 Jun 2024 8:00 AM ISTAlopecia areata (AA) is an autoimmune disease characterized by hair loss, which occurs when T cells of the immune system mistakenly attack hair...
Topical STS-01 Hits Efficacy Endpoints in Mild to Moderate Alopecia patients in Phase 2 trial Dr. Kamal Kant Kohli5 Jun 2024 8:00 PM ISTSoterios Pharma, a privately held clinical-stage pharmaceutical company, today announced positive topline results from its randomised,...
Photobiomodulation offers safe and effective treatment for variety of skin conditions, says new research Medha Baranwal14 March 2024 11:45 PM ISTUSA: A recent medical education article published in the Journal of the American Academy of Dermatology reviews the various clinical applications of...
